S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
GE   11.01 (+0.18%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
GE   11.01 (+0.18%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
GE   11.01 (+0.18%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
GE   11.01 (+0.18%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
Log in

NASDAQ:HZNP - Horizon Therapeutics Stock Price, Forecast & News

$31.97
+0.08 (+0.25 %)
(As of 12/10/2019 04:00 PM ET)
Today's Range
$31.48
Now: $31.97
$32.24
50-Day Range
$27.40
MA: $30.45
$32.78
52-Week Range
$17.94
Now: $31.97
$33.21
Volume1.16 million shs
Average Volume1.29 million shs
Market Capitalization$5.99 billion
P/E Ratio17.47
Dividend YieldN/A
Beta0.87
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:HZNP
CUSIP44047T10
Phone011-353-1772-2100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.21 billion
Cash Flow$3.93 per share
Book Value$6.29 per share

Profitability

Net Income$-74,190,000.00

Miscellaneous

Employees1,000
Market Cap$5.99 billion
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive HZNP News and Ratings via Email

Sign-up to receive the latest news and ratings for HZNP and its competitors with MarketBeat's FREE daily newsletter.


Horizon Therapeutics (NASDAQ:HZNP) Frequently Asked Questions

What is Horizon Therapeutics' stock symbol?

Horizon Therapeutics trades on the NASDAQ under the ticker symbol "HZNP."

How were Horizon Therapeutics' earnings last quarter?

Horizon Therapeutics PLC (NASDAQ:HZNP) announced its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported $0.64 EPS for the quarter, beating the Zacks' consensus estimate of $0.50 by $0.14. The biopharmaceutical company earned $335.50 million during the quarter, compared to analyst estimates of $330.60 million. Horizon Therapeutics had a net margin of 5.25% and a return on equity of 27.71%. The firm's revenue for the quarter was up 3.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.65 earnings per share. View Horizon Therapeutics' Earnings History.

When is Horizon Therapeutics' next earnings date?

Horizon Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Horizon Therapeutics.

What price target have analysts set for HZNP?

12 analysts have issued 1-year target prices for Horizon Therapeutics' shares. Their forecasts range from $27.00 to $38.00. On average, they expect Horizon Therapeutics' share price to reach $34.00 in the next twelve months. This suggests a possible upside of 6.4% from the stock's current price. View Analyst Price Targets for Horizon Therapeutics.

What is the consensus analysts' recommendation for Horizon Therapeutics?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics in the last year. There are currently 1 hold rating and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Horizon Therapeutics.

What are Wall Street analysts saying about Horizon Therapeutics stock?

Here are some recent quotes from research analysts about Horizon Therapeutics stock:
  • 1. According to Zacks Investment Research, "Horizon’s efforts to develop its pipeline are impressive. The company's BLA for teprotumumab was accepted by the FDA in September. The FDA set an action date of Mar 8, 2020. A potential approval will significantly boost the company’s performance. The company also initiated the MIRROR study on Krystexxa in the second quarter. The study is designed to support the potential for registration of the drug.  Horizon expects continued strong growth for Krystexxa, going forward, and teprotumumab, beginning 2020. Shares of the company have outperformed the industry in the past year. However, it faces intense competition from pharmaceutical and biotechnology companies and universities. Estimates are stable ahead of Q3 results." (10/29/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We have updated our financial model to include: 1) HZNP’s recent equity offering, and 2) sales for teprotumumab starting in 2020, given the positive Phase 3 results earlier this year. Both the equity raise and positive Phase 3 data support our OW rating on HZNP shares. Therefore, we are raising our PT to $32 from $26. The increase in our PT is driven by upward earnings revisions for 2020+ given we now include risk adjusted sales for teprotumumab in our financial model." (4/2/2019)
  • 3. Mizuho analysts commented, "We believe the event could have +10% upside/-30% downside to the stock (and is risky), because expectations for a positive read-out are already quite high. HZNP already advanced +17% YTD into the event. The company has discussed with us the opportunity as capturing 50% share in the 15,000-20,000 moderate/ severe active TED patients, with a $100K net price for treatment to achieve its estimates of >$750M. In contrast, we currently assume a ~15% share, and net price of $210K/treatment in 2020, with net price increases of 5% thereafter (based on prior mgmt. commentary on Orphan pricing). We will update our estimates after the data, which we believe will determine the commercial attractiveness of this compound. We reiterate our Neutral rating, and continue to view 2019 consensus earnings estimates as too high." (2/7/2019)

Has Horizon Therapeutics been receiving favorable news coverage?

Media coverage about HZNP stock has trended somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Horizon Therapeutics earned a news sentiment score of 1.8 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Horizon Therapeutics.

Who are some of Horizon Therapeutics' key competitors?

What other stocks do shareholders of Horizon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics investors own include Opko Health (OPK), Alibaba Group (BABA), Netflix (NFLX), TherapeuticsMD (TXMD), Celgene (CELG), Gilead Sciences (GILD), Allergan (AGN), NVIDIA (NVDA), Bank of America (BAC) and Geron (GERN).

Who are Horizon Therapeutics' key executives?

Horizon Therapeutics' management team includes the folowing people:
  • Mr. Timothy P. Walbert, Chairman, Pres & CEO (Age 52)
  • Mr. Paul W. Hoelscher, Exec. VP & CFO (Age 54)
  • Dr. Shao-Lee Lin M.D., Ph.D., Exec. VP, Head of R&D and Chief Scientific Officer (Age 52)
  • Mr. Barry J. Moze, Exec. VP & Chief Admin. Officer (Age 65)
  • Mr. Robert F. Carey, Exec. VP & Chief Bus. Officer (Age 60)

Who are Horizon Therapeutics' major shareholders?

Horizon Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Scopia Capital Management LP (2.25%), State Street Corp (1.38%), Eagle Asset Management Inc. (1.34%), Emerald Advisers LLC (0.65%), Emerald Mutual Fund Advisers Trust (0.63%) and Rhenman & Partners Asset Management AB (0.55%). Company insiders that own Horizon Therapeutics stock include Brian K Beeler, Geoffrey M Curtis, Irina Konstantinovsky, James Samuel Shannon, Jeff Kent, Paul W Hoelscher, Timothy P Walbert and Vikram Karnani. View Institutional Ownership Trends for Horizon Therapeutics.

Which institutional investors are selling Horizon Therapeutics stock?

HZNP stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, Eagle Asset Management Inc., Emerald Advisers LLC, Scopia Capital Management LP, Parametric Portfolio Associates LLC, Maverick Capital Ltd., Russell Investments Group Ltd. and Massachusetts Financial Services Co. MA. Company insiders that have sold Horizon Therapeutics company stock in the last year include Brian K Beeler, Geoffrey M Curtis, Irina Konstantinovsky, James Samuel Shannon, Jeff Kent, Paul W Hoelscher, Timothy P Walbert and Vikram Karnani. View Insider Buying and Selling for Horizon Therapeutics.

Which institutional investors are buying Horizon Therapeutics stock?

HZNP stock was bought by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Millennium Management LLC, First Trust Advisors LP, 1492 Capital Management LLC, State of New Jersey Common Pension Fund D, California Public Employees Retirement System, John G Ullman & Associates Inc. and Chartwell Investment Partners LLC. View Insider Buying and Selling for Horizon Therapeutics.

How do I buy shares of Horizon Therapeutics?

Shares of HZNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Horizon Therapeutics' stock price today?

One share of HZNP stock can currently be purchased for approximately $31.95.

How big of a company is Horizon Therapeutics?

Horizon Therapeutics has a market capitalization of $5.98 billion and generates $1.21 billion in revenue each year. The biopharmaceutical company earns $-74,190,000.00 in net income (profit) each year or $1.83 on an earnings per share basis. Horizon Therapeutics employs 1,000 workers across the globe.View Additional Information About Horizon Therapeutics.

What is Horizon Therapeutics' official website?

The official website for Horizon Therapeutics is http://www.horizontherapeutics.com/.

How can I contact Horizon Therapeutics?

Horizon Therapeutics' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, DUBLIN L2, D04 C5Y6. The biopharmaceutical company can be reached via phone at 011-353-1772-2100 or via email at [email protected]


MarketBeat Community Rating for Horizon Therapeutics (NASDAQ HZNP)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  784 (Vote Outperform)
Underperform Votes:  397 (Vote Underperform)
Total Votes:  1,181
MarketBeat's community ratings are surveys of what our community members think about Horizon Therapeutics and other stocks. Vote "Outperform" if you believe HZNP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HZNP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel